TG Therapeutics
TGTX
308 hedge funds and large institutions have $2.38B invested in TG Therapeutics in 2024 Q3 according to their latest regulatory filings, with 96 funds opening new positions, 94 increasing their positions, 74 reducing their positions, and 44 closing their positions.
118% more first-time investments, than exits
New positions opened: 96 | Existing positions closed: 44
52% more call options, than puts
Call options by funds: $70.9M | Put options by funds: $46.8M
42% more capital invested
Capital invested by funds: $1.67B → $2.38B (+$707M)
27% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 74
19% more funds holding
Funds holding: 259 → 308 (+49)
5.1% more ownership
Funds ownership: 60.56% → 65.67% (+5.1%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$231M |
| 2 |
State Street
Boston,
Massachusetts
|
+$52.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$37M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$25M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$37.9M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$36.5M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$32.8M |
| 4 |
Millennium Management
New York
|
-$31.6M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$25M |
TGTX Hedge Fund Activity: Q3 2024 in Review
308 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2024, worth a combined $2.38B — up 42% from $1.67B a quarter earlier.
Buyers outnumbered sellers: 96 funds opened new TGTX positions and 44 closed out — a net gain of 52 holders — while 94 added to existing stakes and 74 trimmed.
The largest buyer was BlackRock, adding an estimated $231M. The largest seller was Citadel Advisors, cutting an estimated $37.9M.
- 308 institutional investors held TG Therapeutics (TGTX) as of Q3 2024, up from 259 in Q2 2024.
- Funds reported $2.38B of TG Therapeutics stock for Q3 2024, up 42% quarter-over-quarter.
- 96 funds opened new TG Therapeutics positions in Q3 2024 and 44 closed out, a net change of +52 holders.
- The largest TG Therapeutics buyer in Q3 2024 was BlackRock, an estimated $231M added.
- The largest TG Therapeutics seller in Q3 2024 was Citadel Advisors, an estimated $37.9M sold.
Based on aggregated 13F filings for Q3 2024.